DNLI
Denali Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.18B
P/E Ratio
—
EPS
$-2.97
Beta
1.10
52W High
$23.77
52W Low
$12.58
50-Day MA
$20.24
200-Day MA
$17.36
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-418.78M |
| EBITDA | $-540.53M |
| Operating Margin | 0.00% |
| Return on Equity | -45.70% |
| Return on Assets | -27.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $6.49 |
| Price-to-Book | 3.12 |
| Price-to-Sales (TTM) | 3643.65 |
| EV/Revenue | 2843.16 |
| EV/EBITDA | 86.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $158.68M |
| Float | $144.16M |
| % Insiders | 9.13% |
| % Institutions | 99.02% |
Historical Volatility
HV 10-Day
47.56%
HV 20-Day
57.03%
HV 30-Day
72.25%
HV 60-Day
62.99%
HV Rank
92.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($35.64 target)
1
Strong Buy17
Buy1
HoldData last updated: 4/29/2026